196,907 research outputs found
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
No full textClonality of B-cells in portal lymphoid infiltrates of HCV infected livers.
No full textReference Author: Facchetti
Hepatocellular carcinoma in HIV hepatitis C virus
No full textPurpose of review Recent data showed that in some settings with adequate resources liver diseases rank first among the causes of death in persons living with HIV (PLHIV). Although liver decompensation is the first cause of hepatic death in PLHIV, hepatocellular carcinoma (HCC) is also emerging as one of the causes of hepatic death in PLHIV. This review analyzes the main data published on HCC in PLHIV in the last 3 years. Recent findings HCC is more common in persons living with HIV than in general population. In PLHIV with a late diagnosis of HCC, less treatable cases and lower survival were described in retrospective studies. New treatment strategies are available for advanced HCC but there are few data available on PLHIV and some open issues. Nevertheless, screening of HIV-infected patients suspected to have cirrhosis seems to be useful and is mandatory in PLHIV and hepatitis C virus (HCV) induced cirrhosis. Together with screening of patients at risk and an early diagnosis, aggressive treatment of the neoplasia including treatment of relapses and maintenance of HIV suppression are the best management strategies for HCC in PLHIV. The role of liver transplantation remains controversial. Summary In the last years, HCC is becoming an important issue in PLHIV. Prevention, screening, and treatment strategies for HCC need to be included in the management of PLHIV
HCV chronic hepatitis in patients with HIV: clinical management issues
No full textAbstract: HIV-hepatitis C virus(HCV) coinfection is common and affects more than one-third of all HIV infected persons worldwide. Prevalence among risk categories varies according to shared risk factors for transmission, mainly intravenous drug use (IDU) and hemophiliacs. Chronic HCV infection seems to accelerate the course of HIV disease, resulting in a worsened clinical and immunological progression. At the same time, several studies suggest that HIV disease modifies the natural history of HCV infection, leading to a faster course of progression from active hepatitis to cirrhosis, to end stage liver disease and death. HCV infection mimics opportunistic diseases because its natural history is significantly accelerated in HIV patients. Since highly active antiretroviral therapy (HAART) has slowed the progression of HIV disease and decreased the rate of HIV associated mortality, the prognosis of HIV disease has been modified. and the need to treat HCV coinfection become a significant issue. Because of the poor response rate obtained by either interferon alone or interferon thrice weekly plus ribavirin, the combination of pegylated interferon and ribavirin will probably become the standard of care. although the clinicians should be aware of the overlapping toxicity of nucleoside analogues and ribavirin. Many selected categories of patients pose particular challenges to physicians treating HCV infection: nonresponders to interferon, cirrhotic patients, and patients infected with both HCV and HBV. Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease
Management of hepatitis C in human immunodeficiency virus-infected patients.
No full textAbstract: Hepatitis C virus-related liver disease and Its associated complications are steadily emerging health concerns in persons co-infected with human immunodeficiency virus. The increasing number of liver-related deaths in human immunodeficiency virus-hepatitis C virus coinfected individuals supports the compelling argument for more aggressive treatment in these patients. The safety and efficacy of interferon/ribavirin in human immunodeficiency virus/hepatitis C virus co-infected patients is currently under, evaluation. Despite well-documented concern over highly active antiretroviral therapy-associated hepatotoxicity human immunodeficiency virus/hepatitis C virus co-infected patients should be offered antiretroviral therapy Since management of co-infected patients is complex a multidisciplinary approach is needed in order to facilitate care and help patients to achieve a positive outcome
Dr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
- …
